期刊文献+

复脉颗粒对心房颤动患者心房重构的临床疗效及其作用机理研究 被引量:3

下载PDF
导出
摘要 目的:观察复脉颗粒治疗房颤的疗效及对房颤患者心房重构的影响。方法:将符合纳入标准的61例房颤患者随机分为2组,对照组30例予常规治疗,治疗组31例在对照组基础上予口服复脉颗粒治疗。分别在治疗前与治疗4周后,记录2组患者B型尿钠肽(BNP)、C-反应蛋白(CRP)、基质金属蛋白酶9(MMP-9)、基质金属蛋白酶抑制因子1(TIMP-1);心房内径(LAD)、射血分数(EF);临床症状的变化,并初步探讨复脉颗粒的作用机理,同时观察2组患者治疗期间的不良反应。结果:治疗组治疗前后平均心室率、BNP、MMP-9、TIMP-1、CRP组内比较,差异均有显著性意义(P<0.05)。上述指标2组治疗后比较,差异也有显著性意义(P<0.05)。2组治疗前后心悸、胸闷、气短、乏力、头晕等中医症状体征积分组内比较,差异均有显著性意义(P<0.05)。2组治疗后比较,差异也有显著性意义(P<0.05)。证候疗效治疗组总有效率为90.32%,对照组为66.67%,2组比较,差异有显著性意义(P<0.05)。在观察过程中,治疗组无不良反应的证据;对照组2例患者出现恶心、腹泻,未予处理,症状消失。结论:复脉颗粒治疗房颤疗效肯定,且无明显毒副反应。
出处 《新中医》 CAS 2014年第11期81-83,共3页 New Chinese Medicine
基金 广东省科技厅计划项目(编号:2010B60900076)
  • 相关文献

参考文献7

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1401
  • 2中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:54-58.
  • 3闫明珠,胡大一.脑利钠肽(BNP)和心房颤动[J].中国民康医学,2006,18(9):393-395. 被引量:9
  • 4Chung MK, Martin DO, Sprecher D, et al. C-reac- tive protein elevation in patients with atrial arrhyth- mias: Inflammatory mechanisms and persistence of atrial fibrillation[J]. Circulation, 2001, 104(24): 86-91.
  • 5Tanaka A, Masuda H. IgE crosslinkage of Fcepsilon re- ceptor I induces both production and activation of matrix metalloproteinase-9 in mast cell [J]. Cell Immunol, 2004, 228(1): 66-75.
  • 6Santhamma KR. Specific cellular proteins associate with angiotensin-converting enzyme and regulate its intracellular transport and cleavage-secretion[J]. J Biol Chem, 2000, 275(30): 253-258.
  • 7Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II type1 receptor antagonist on electrical and structural emodeling in atrial fibrillation[J]. Am Coil 2003. 41112): 219-221.

二级参考文献21

  • 1Sodoh T, Kangawa K, Minamino N,et al. A new natriuretic peptide in porcine brain. Nature, 1988,332:78-81.
  • 2Ogawa Y, Itoh H, Nakao K. Molecular biology and biochemistry of natriuretic peptide family. Clin Exp Pharmacol Physiol, 1995,22:49 - 53.
  • 3Tuinenburg AE, Brundel BJ,et al. Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. J cardiovasc Electrophysiol. 1999 Jun;10(6):827 -35.
  • 4Inouc S. Murakami Y, et al. Atrium as a source of BNP in patients with atrial fibrillation. J Card Fail, 2000 Jun;6(2):92 -6.
  • 5Helme Silvet, Yinong Young- Xu. BNP is elevated in outpatients with atrial fibrillation. Am. J Cardiol. 2003 Nov;92(9):c60 -6.
  • 6Ohta Y,Shimada T,et al. Drop in plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation. Can J cardiol. 2001 Apr; 17 (4) :415 - 20.
  • 7Nakamura M, Kawata Y, Yoshida H, et al. Relationship between plasma atrial and brain natriaretie peptide concentration and hemodynamic parametets during percutaneous transvenous mitral valvulotomy in patients with mitral stenosis. Am Heart J. 1992; 124:1283-1288.
  • 8Frustaci A, Chimenti C, et al, Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180-1184.
  • 9Horie H ,Tsutamoto T, Minai K, et al. Brain natriuretic peptide predicts chronic atrial fibrillation after ventricular pacing in patients with sick sinus syndrome. Jpn Circ J ,2000,64:965-970.
  • 10Mabuchi N ,Tsutamoto T,et al. Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure. Jpn Circ J,2000,64:765-771.

共引文献2660

同被引文献60

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部